A class II MHC-targeted vaccine elicits immunity against #SARS-CoV-2 and its variants

Vaccines remain the best hope of curtailing SARS-CoV-2 transmission, morbidity, and mortality. Currently available vaccines require cold storage and sophisticated manufacturing capacity, complicating their distribution, especially in less developed countries. We report a protein-based SARS-CoV-2 vaccine that directly and specifically targets antigen-presenting cells. It consists of the SARS-CoV-2 Spike receptor-binding domain (SpikeRBD) fused to a … Continue reading A class II MHC-targeted vaccine elicits immunity against #SARS-CoV-2 and its variants